Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017

Executive Summary

Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.

You may also be interested in...

Stockwatch: Mistaken Acquisitions Dim Earnings Season

Fourth-quarter earnings reports from J&J, Novartis, AbbVie and Biogen all missed on sales but more worryingly, lower sales from some recent acquisitions contributed to the missed expectations. The time from child star to problem child seems to be shorter than I remember.

Bioverativ Hits The Street Ready To Expand In Blood Disorders

Bioverativ will spin out from Biogen Feb. 1 as a biotech focused on rare blood disorders, particularly hemophilia. With two marketed drugs, a lifecycle management strategy and leverage to bring in new assets, CEO John Cox says the company is ready to go it alone.

Sobi Seeks New CEO Who Is Around Sweden, Europe As Business Grows

Sobi's outgoing US-based CEO says his extended handover will “maintain continuity” as Sweden's rare disease specialist searches for a successor who will "stay closer to home" as it conducts key product launches.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts